Want to see HK:2877 full AI Analyst Report?
2877 Stock Chart & Stats
HK$8.52
HK$0.10(1.21%)
At close: 4:00 PM EDT
HK$8.52
HK$0.10(1.21%)
Day’s Range― - ―
52-Week RangeHK$7.21 - HK$10.47
Previous CloseN/A
Volume411.00K
Average Volume (3M)2.09M
Market Cap
HK$6.30B
Enterprise Value-HK$2.78K
Total Cash (Recent Filing)HK$7.54B
Total Debt (Recent Filing)HK$312.23M
Price to Earnings (P/E)6.8
Beta0.47
Next Earnings
Mar 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield17.03%
Share Statistics
EPS (TTM)1.05
Shares Outstanding827,000,000
10 Day Avg. Volume2,076,100
30 Day Avg. Volume2,091,388
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.72
Price to Sales (P/S)1.86
P/FCF Ratio5.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.27
Revenue Forecast (FY)HK$3.03B
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained high gross and operating margins indicate strong product economics in the company’s proprietary TCM portfolio. This profitability provides resilience against cost pressure and supports continued investment in research, manufacturing quality, hospital access, and distribution over the coming quarters.
Very Low LeverageMinimal leverage materially limits interest burdens, refinancing exposure, and balance-sheet stress during weaker demand periods. The conservative capital structure preserves financial flexibility to fund operations, product development, and shareholder distributions without relying heavily on external borrowing.
Positive Cash GenerationConsistently positive free cash flow indicates that reported profitability is being converted into internally generated funds. Stronger 2025 cash generation can support working capital, research and development, manufacturing investment, and distributions while reducing dependence on debt financing.
Bears Say
Revenue ContractionThe sustained weakening in revenue momentum signals pressure on product volumes, pricing, or mix across the TCM portfolio. If contraction persists, lower operating scale could reduce the company’s ability to absorb fixed manufacturing, quality-control, and commercial costs.
Margin SofteningAlthough margins remain healthy, the decline from the 2023 peak suggests that the company’s earnings conversion is not fully stable. Continued pressure from product mix, pricing, or operating costs could reduce the benefit of its otherwise strong gross-margin structure over the next several quarters.
Volatile Cash-Flow GrowthYear-to-year volatility in free cash flow makes the timing and reliability of internally funded investment less predictable. Even with positive cash generation, uneven conversion can complicate planning for research, production capacity, commercial spending, and shareholder returns.
China Shineway Pharmaceutical Group Limited News
2877 FAQ
What was China Shineway Pharmaceutical Group Limited’s price range in the past 12 months?
China Shineway Pharmaceutical Group Limited lowest stock price was HK$7.21 and its highest was HK$10.47 in the past 12 months.
What is China Shineway Pharmaceutical Group Limited’s market cap?
China Shineway Pharmaceutical Group Limited’s market cap is HK$6.30B.
When is China Shineway Pharmaceutical Group Limited’s upcoming earnings report date?
China Shineway Pharmaceutical Group Limited’s upcoming earnings report date is Mar 30, 2027 which is in 179 days.
How were China Shineway Pharmaceutical Group Limited’s earnings last quarter?
China Shineway Pharmaceutical Group Limited released its earnings results on Aug 27, 2026. The company reported HK$0.639 earnings per share for the quarter.
Is China Shineway Pharmaceutical Group Limited overvalued?
According to Wall Street analysts China Shineway Pharmaceutical Group Limited’s price is currently Overvalued.
Does China Shineway Pharmaceutical Group Limited pay dividends?
China Shineway Pharmaceutical Group Limited pays a Notavailable dividend of HK$0.995 which represents an annual dividend yield of 17.03%. See more information on China Shineway Pharmaceutical Group Limited dividends here
What is China Shineway Pharmaceutical Group Limited’s EPS estimate?
China Shineway Pharmaceutical Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Shineway Pharmaceutical Group Limited have?
China Shineway Pharmaceutical Group Limited has 827,000,000 shares outstanding.
What happened to China Shineway Pharmaceutical Group Limited’s price movement after its last earnings report?
China Shineway Pharmaceutical Group Limited reported an EPS of HK$0.639 in its last earnings report. Following the earnings report the stock price went up 5.984%.
Which hedge fund is a major shareholder of China Shineway Pharmaceutical Group Limited?
Currently, no hedge funds are holding shares in HK:2877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Shineway Pharmaceutical Group Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
17.03%
Trailing 12-Months
Asset Growth
6.18%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
China Shineway Pharmaceutical Group Limited
As an investment holding enterprise, China Shineway Pharmaceutical Group Limited is dedicated to the development, production, and sale of traditional Chinese medicines throughout the People's Republic of China and Hong Kong. Its extensive product range includes modern Chinese pharmaceuticals delivered as soft capsules, granular preparations, and injectable forms, alongside specialized Traditional Chinese Medicine (TCM) Formula Granules. These offerings cater to a broad spectrum of therapeutic needs, such as cardiovascular and cerebrovascular health, anti-viral applications, orthopedic conditions, pediatric ailments, gynecological care, and gastrointestinal issues. Furthermore, the company is involved in the trading of agricultural commodities. Founded in 2004, its headquarters are situated in Shijiazhuang, PRC, and it functions as a subsidiary of Forway Investment Limited.
Technical Analysis
The United Laboratories International Holdings
―
China Traditional Chinese Medicine Holdings Co
―
Jacobson Pharma Corporation Limited
―
Grand Pharmaceutical Group Limited
―
Shandong Xinhua Pharmaceutical Company Limited Class H
―